• MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

    Источник: Nasdaq GlobeNewswire / 02 сен 2021 07:05:00   America/Chicago

    GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

    Conference Call Details

    Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

    About MaxCyte

    MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

    MaxCyte Contacts:

    MaxCyte Inc.
    Doug Doerfler, Chief Executive Officer
    Amanda Murphy, Chief Financial Officer
    +1 301-944-1660
      
    Nominated Adviser and Joint Corporate Broker
    Panmure Gordon
    Emma Earl / Freddy Crossley
    Corporate Broking
    Rupert Dearden
    +44 (0)20 7886 2500
      
    Joint Corporate Broker 
    Numis Securities Limited
    James Black / Duncan Monteith / Matthew O’Dowd
    +44 (0)20 7260 1000
      
    Joint Corporate Broker 
    Stifel Nicolaus Europe Limited
    Healthcare Investment Banking
    Nicholas Moore / Ben Maddison / Samira Essebiyea
    Corporate Broking
    Nick Adams
    +44 (0) 20 7710 7600
      
    UK IR Adviser 
    Consilium Strategic Communications
    Mary-Jane Elliott
    Chris Welsh
    +44 (0)203 709 5700
    maxcyte@consilium-comms.com
      
    US IR Adviser
    Gilmartin Group
    David Deuchler, CFA
    +1 415-937-5400
    ir@maxcyte.com
      
    US Media Relations
    Jamie Lacey-Moreira
    PressComm PR, LLC
    +1 410 299-3310
    jamielacey@presscommpr.com


    Primary Logo

Опубликовать